Compare NextEra Energy, Inc. (NEE) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NextEra Energy, Inc. vs Sanofi SA — how do they compare? NextEra Energy, Inc. trades at $82.99 (market cap $174.87B), while Sanofi SA trades at $42.7 (market cap $104.06B). The key difference: NextEra Energy, Inc. is the larger of the two by market cap, and Sanofi SA pays the higher dividend (5.61%). Which is the better fit depends on your goals.
| NEE | SNY | |
|---|---|---|
Market Cap | $174.87B | $104.06B |
Sector | Utilities | Health |
52-Week High | $97.88 | $52.34 |
52-Week Low | $69.83 | $41.33 |
Enterprise Value | $282.20B | $124.09B |
Dividend Yield | 2.97% | 5.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NextEra Energy (NEE) trades at $83.83, up 0.48% with a bearish technical signal despite strong analyst support. The company shows solid fundamentals with Q1 and Q2 2026 earnings beats, a 32.4% net income margin, and recent positive developments including a $1.9 billion DOE loan for nuclear plant restart. Cash flow improved to $1.6B net in 2025, though debt-to-asset ratio rose to 47.6%.
Outlook remains positive with 66.7% analyst buy ratings and a $100.20 consensus price target offering 19.5% upside. Key risks include rising leverage, competitive pressures, and execution of growth projects. The stock presents a growth opportunity in renewable energy with institutional backing, balanced by macroeconomic and regulatory uncertainties.
Sanofi (SNY) trades at $43.155, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported strong Q2 2026 earnings, beating expectations with EPS of $1.21 versus $1.10 expected, and raised full-year guidance. Recent FDA approvals for COVID vaccines and EU approval for MenQuadfi in infants provide positive catalysts, though pipeline setbacks with an eczema drug withdrawal create uncertainty.
SNY presents a mixed outlook with solid fundamentals including a 5.4% dividend yield and reasonable valuation (P/E 22.94), but faces execution risks under new CEO leadership. Analyst consensus leans Hold (51.86%) with price target of $49.50, suggesting moderate upside potential. Key risks include drug pipeline challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NextEra Energy, Inc.
NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
